Analysts Set Galapagos NV (NASDAQ:GLPG) Target Price at $31.00

Shares of Galapagos NV (NASDAQ:GLPG) have been given an average rating of “Reduce” by the six brokerages that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating and five have issued a hold rating on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $30.75.

Several equities research analysts recently weighed in on GLPG shares. Leerink Partners started coverage on shares of Galapagos in a research report on Monday, September 9th. They set a “market perform” rating and a $24.00 price target for the company. Raymond James downgraded shares of Galapagos from an “outperform” rating to a “market perform” rating in a research report on Friday, August 2nd. Royal Bank of Canada reduced their price target on shares of Galapagos from $32.00 to $30.00 and set a “sector perform” rating for the company in a research report on Friday, November 1st. Finally, Leerink Partnrs upgraded shares of Galapagos to a “hold” rating in a report on Monday, September 9th.

Galapagos Stock Up 0.1 %

Shares of NASDAQ GLPG opened at $26.74 on Wednesday. Galapagos has a fifty-two week low of $24.16 and a fifty-two week high of $42.46. The company has a 50 day simple moving average of $29.15 and a two-hundred day simple moving average of $27.68.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Headlands Technologies LLC boosted its stake in shares of Galapagos by 949.3% during the 1st quarter. Headlands Technologies LLC now owns 787 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 712 shares during the last quarter. GAMMA Investing LLC boosted its stake in shares of Galapagos by 140.7% during the 3rd quarter. GAMMA Investing LLC now owns 1,259 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 736 shares during the last quarter. Signaturefd LLC boosted its stake in shares of Galapagos by 48.1% during the 2nd quarter. Signaturefd LLC now owns 3,872 shares of the biotechnology company’s stock worth $96,000 after acquiring an additional 1,258 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in shares of Galapagos by 63.2% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 3,899 shares of the biotechnology company’s stock worth $112,000 after acquiring an additional 1,510 shares during the last quarter. Finally, Rhumbline Advisers boosted its stake in shares of Galapagos by 21.6% during the 2nd quarter. Rhumbline Advisers now owns 4,578 shares of the biotechnology company’s stock worth $113,000 after acquiring an additional 814 shares during the last quarter. Hedge funds and other institutional investors own 32.46% of the company’s stock.

Galapagos Company Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.